Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic iPS Cell-derived Cardiomyocyte Sheet for Ischemic Cardiomyopathy
NCT04696328Phase 1Unknown
- Sponsor
- The University of Osaka
- Start
- Dec 2019
- Primary completion
- May 2022
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Human (allogeneic) iPS cell derived-cardiomyocyte sheet in ischemic cardiomyopathy (ICM), sponsored by The University of Osaka. Primary endpoints: Number of patients with improved LVEF at 26 weeks, Incidence of adverse events and defects at 52 weeks and 6 more. Status: unknown.
02
Drugs
Human (allogeneic) iPS cell derived-cardiomyocyte sheet
03
Conditions
ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT04696328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04696328.